Thousands of patients in the UK are to receive medical cannabis as part of Europe’s largest national medical cannabis registry.
Project TWENTY21 is being organised by the independent scientific body Drug Science and is supported by the Royal College of Psychiatrists and the British Pain Society.
The project expects to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medicinal cannabis. Treatment will be provided at a network of clinics across the UK.
According to Drug Science, the primary objective is to develop a body of real-world evidence on the efficacy, safety and patient-reported outcomes.
In the first instance, Project TWENTY21 will focus on seven conditions in patients for whom alternative treatment has failed. The target areas are:
- Anxiety disorder
- Chronic pain
- Epilepsy
- Multiple sclerosis
- Post-traumatic stress disorder
- Substance use disorder (as a harm reduction strategy)
- Tourette’s syndrome
The General Medical Council registered consultant psychiatrists, neurologists and pain specialists who are interested in contributing to Project Twenty21 data collection, are requested to contact prescribers@drugscience.org.uk.
